Cognitive Impairment in Major Depressive Disorder Clinical Relevance, Biological Substrates, and Treatment Opportunities
Book contents
- Cognitive Impairment in Major Depressive DisorderClinical Relevance, Biological Substrates, and Treatment Opportunities
- Cognitive Impairment in Major Depressive Disorder
- Copyright page
- Contents
- Figures
- Tables
- Contributors
- Preface
- Abbreviations
- Part I Clinical relevance of cognitive dysfunction in major depressive disorder
- Part II Underlying biological substrates associated with cognitive dysfunction in major depressive disorder
- Part III Evaluating cognitive dysfunction in major depressive disorder
- Part IV Treatment opportunities for ameliorating cognitive dysfunction in major depressive disorder
- 18 Neuroscience of functional outcomes and treatment targets in major depressive disorder
- 19 Treatment of cognitive dysfunction in adults with major depressive disorder
- 20 A novel treatment targeting cognitive dysfunction in mood disorders
- 21 Cognitive remediation for major depressive disorder
- 22 Exercise and cognition
- Index
- References
20 - A novel treatment targeting cognitive dysfunction in mood disorders
from Part IV - Treatment opportunities for ameliorating cognitive dysfunction in major depressive disorder
Published online by Cambridge University Press: 05 March 2016
Book contents
- Cognitive Impairment in Major Depressive DisorderClinical Relevance, Biological Substrates, and Treatment Opportunities
- Cognitive Impairment in Major Depressive Disorder
- Copyright page
- Contents
- Figures
- Tables
- Contributors
- Preface
- Abbreviations
- Part I Clinical relevance of cognitive dysfunction in major depressive disorder
- Part II Underlying biological substrates associated with cognitive dysfunction in major depressive disorder
- Part III Evaluating cognitive dysfunction in major depressive disorder
- Part IV Treatment opportunities for ameliorating cognitive dysfunction in major depressive disorder
- 18 Neuroscience of functional outcomes and treatment targets in major depressive disorder
- 19 Treatment of cognitive dysfunction in adults with major depressive disorder
- 20 A novel treatment targeting cognitive dysfunction in mood disorders
- 21 Cognitive remediation for major depressive disorder
- 22 Exercise and cognition
- Index
- References
- Type
- Chapter
- Information
- Cognitive Impairment in Major Depressive DisorderClinical Relevance, Biological Substrates, and Treatment Opportunities, pp. 289 - 305Publisher: Cambridge University PressPrint publication year: 2016
References
Adamcio, B., Sargin, D., Stradomska, A., Medrihan, L., Gertler, C., Theis, F., … Ehrenreich, H. (2008). Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biology, 6: 37.CrossRefGoogle ScholarPubMed
Banks, W. A., Jumbe, N. L., Farrell, C. L., Niehoff, M. L., & Heatherington, A. C. (2004). Passage of erythropoietic agents across the blood–brain barrier: A comparison of human and murine erythropoietin and the analog darbepoetin alfa. European Journal of Pharmacology, 505(1–3): 93–101.Google Scholar
Bora, E., Harrison, B. J., Yucel, M., & Pantelis, C. (2013). Cognitive impairment in euthymic major depressive disorder: A meta-analysis. Psychological Medicine, 43(10): 2017–2026.Google Scholar
Bourne, C., Aydemir, O., Balanza-Martinez, V., Bora, E., Brissos, S., Cavanagh, J. T., … Goodwin, G. M. (2013). Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: An individual patient data meta-analysis. Acta Psychiatrica Scandinavica, 128(3): 149–162.Google Scholar
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., … Cerami, A. (2000). Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury. Proceedings of the National Academy of Sciences of the United States of America, 97(19): 10526–10531.Google Scholar
Buemi, M., Cavallaro, E., Floccari, F., Sturiale, A., Aloisi, C., Trimarchi, M., … Frisina, N. (2003). The pleiotropic effects of erythropoietin in the central nervous system. Journal of Neuropathology and Experimental Neurology, 62(3): 228–236.Google Scholar
Byts, N. & Siren, A. L. (2009). Erythropoietin: A multimodal neuroprotective agent. Experimental & Translational Stroke Medicine, 1: 4.CrossRefGoogle ScholarPubMed
Digicaylioglu, M., Bichet, S., Marti, H. H., Wenger, R. H., Rivas, L. A., Bauer, C., & Gassmann, M. (1995). Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proceedings of the National Academy of Sciences of the United States of America, 92(9): 3717–3720.Google Scholar
Dirnagl, U., Simon, R. P., & Hallenbeck, J. M. (2003). Ischemic tolerance and endogenous neuroprotection. Trends in Neurosciences, 26(5): 248–254.Google Scholar
Ehrenreich, H., Fischer, B., Norra, C., Schellenberger, F., Stender, N., Stiefel, M., … Bartels, C. (2007a). Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain, 130(Pt. 10): 2577–2588.CrossRefGoogle ScholarPubMed
Ehrenreich, H., Hinze-Selch, D., Stawicki, S., Aust, C., Knolle-Veentjer, S., Wilms, S., … Krampe, H. (2007b). Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Molecular Psychiatry, 12(2): 206–220.Google Scholar
Eriksson, T. M., Delagrange, P., Spedding, M., Popoli, M., Mathe, A. A., Ogren, S. O., & Svenningsson, P. (2011). Emotional memory impairments in a genetic rat model of depression: Involvement of 5-HT/MEK/Arc signaling in restoration. Molecular Psychiatry, 17(2): 173–184.Google Scholar
Ge, X. H., Zhu, G. J., Geng, D. Q., Zhang, Z. J., & Liu, C. F. (2012). Erythropoietin attenuates 6-hydroxydopamine-induced apoptosis via glycogen synthase kinase 3beta-mediated mitochondrial translocation of Bax in PC12 cells. Neurological Sciences, 33(6): 1249–1256.CrossRefGoogle ScholarPubMed
Girgenti, M. J., Hunsberger, J., Duman, C. H., Sathyanesan, M., Terwilliger, R., & Newton, S. S. (2009). Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biological Psychiatry, 66(3): 267–274.Google Scholar
Hamilton, J. P. & Gotlib, I. H. (2008). Neural substrates of increased memory sensitivity for negative stimuli in major depression. Biological Psychiatry, 63(12): 1155–1162.Google Scholar
Harmer, C. J. (2010). Antidepressant drug action: A neuropsychological perspective. Depression and Anxiety, 27(3): 231–233.CrossRefGoogle Scholar
Inkster, B., Nichols, T. E., Saemann, P. G., Auer, D. P., Holsboer, F., Muglia, P., & Matthews, P. M. (2009). Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. Archives of General Psychiatry, 66(7): 721–728.Google Scholar
Jelkmann, W., Bohlius, J., Hallek, M., & Sytkowski, A. J. (2008). The erythropoietin receptor in normal and cancer tissues. Critical Reviews in Oncology/Hematology, 67(1): 39–61.Google Scholar
Kastner, A., Grube, S., El-Kordi, A., Stepniak, B., Friedrichs, H., Sargin, D., … Ehrenreich, H. (2012). Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia. Molecular Medicine, 18: 1029–1040.Google Scholar
Leconte, C., Bihel, E., Lepelletier, F. X., Bouet, V., Saulnier, R., Petit, E., … Schumann-Bard, P. (2011). Comparison of the effects of erythropoietin and its carbamylated derivative on behaviour and hippocampal neurogenesis in mice. Neuropharmacology, 60(2–3): 354–364.CrossRefGoogle ScholarPubMed
Marti, H. H., Wenger, R. H., Rivas, L. A., Straumann, U., Digicaylioglu, M., Henn, V., … Gassmann, M. (1996). Erythropoietin gene expression in human, monkey and murine brain. European Journal of Neuroscience, 8(4): 666–676.CrossRefGoogle ScholarPubMed
Miskowiak, K., Ehrenreich, H., Christensen, E. M., Kessing, L. V., & Vinberg, M. (2014a). Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: A double-blind, randomized, placebo-controlled phase 2 trial. Journal of Clinical Psychiatry, 75(12): 1347–1355.Google Scholar
Miskowiak, K. W., Favaron, E., Hafizi, S., Inkster, B., Goodwin, G. M., Cowen, P. J., & Harmer, C. J. (2009). Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. Psychopharmacology (Berlin), 207(1): 133–142.CrossRefGoogle ScholarPubMed
Miskowiak, K. W., Favaron, E., Hafizi, S., Inkster, B., Goodwin, G. M., Cowen, P. J., & Harmer, C. J. (2010a). Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients. Psychopharmacology (Berlin), 210(3) 419–428.Google Scholar
Miskowiak, K., Inkster, B., O’Sullivan, U., Selvaraj, S., Goodwin, G. M., & Harmer, C. J. (2008a). Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Experimental Brain Research, 184(3): 313–321.Google Scholar
Miskowiak, K., Inkster, B., Selvaraj, S., Goodwin, G., & Harmer, C. (2007a). Erythropoietin has no effect on hippocampal response during memory retrieval 3 days post-administration. Psychopharmacology (Berlin), 195(3): 451–453.CrossRefGoogle ScholarPubMed
Miskowiak, K., Inkster, B., Selvaraj, S., Wise, R., Goodwin, G. M., & Harmer, C. J. (2008b). Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration. Neuropsychopharmacology, 33(3): 611–618.Google Scholar
Miskowiak, K., O’Sullivan, U., & Harmer, C. J. (2007b). Erythropoietin enhances hippocampal response during memory retrieval in humans. Journal of Neuroscience, 27(11): 2788–2792.Google Scholar
Miskowiak, K., O’Sullivan, U., & Harmer, C. J. (2007c). Erythropoietin reduces neural and cognitive processing of fear in human models of antidepressant drug action. Biological Psychiatry, 62(11): 1244–1250.Google Scholar
Miskowiak, K. W., Vinberg, M., Christensen, E. M., Bukh, J. D., Harmer, C. J., Ehrenreich, H., & Kessing, L. V. (2014b). Recombinant human erythropoietin for treating treatment-resistant depression: A double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology, 39(6): 1399–1408.Google Scholar
Miskowiak, K. W., Vinberg, M., Harmer, C. J., Ehrenreich, H., Knudsen, G. M., Macoveanu, J., … Kessing, L. V. (2010b). Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials, 11: 97.Google Scholar
Miskowiak, K. W., Vinberg, M., Macoveanu, J., Ehrenreich, H., Køster, N., Inkster, B., … Siebner, H. R. (2015). Effects of erythropoietin on hippocampal volume and memory in mood disorders. Biological Psychiatry, 78(4): 270–277.Google Scholar
Mogensen, J., Miskowiak, K., Sørensen, T. A., Lind, C. T., Olsen, N. V., Springborg, J. B., & Mala, H. (2004). Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats. Pharmacology, Biochemistry, and Behavior, 77(2): 381–390.Google Scholar
Nakamura, T., Ebihara, I., Shimada, N., & Koide, H. (1998). Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients. American Journal of Medical Sciences, 315(3): 199–201.Google Scholar
Sargin, D., El-Kordi, A., Agarwal, A., Muller, M., Wojcik, S. M., Hassouna, I., … Ehrenreich, H. (2011). Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice. BMC Biology, 9: 27.Google Scholar
Sargin, D., Friedrichs, H., El-Kordi, A., & Ehrenreich, H. (2010). Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research. Best Practice & Research. Clinical Anaesthesiology, 24(4): 573–594.Google Scholar
Siren, A. L., Fasshauer, T., Bartels, C., & Ehrenreich, H. (2009). Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics, 6(1): 108–127.Google Scholar
Tsai, P. T., Ohab, J. J., Kertesz, N., Groszer, M., Matter, C., Gao, J., … Carmichael, S. T. (2006). A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. Journal of Neuroscience, 26(4): 1269–1274.Google Scholar
Tse, S., Chan, S., Ng, K. L., & Yatham, L. N. (2014). Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar Disorders, 16(3): 217–229.Google Scholar
Wustenberg, T., Begemann, M., Bartels, C., Gefeller, O., Stawicki, S., Hinze-Selch, D., … Ehrenreich, H. (2011). Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Molecular Psychiatry, 16(1): 26–36.Google Scholar